HP518 yapezedwa ndikupangidwa ndi nsanja ya Hinova yomwe imayang'anira kuwononga mapuloteni. Ili ndi kuthekera kothana ndi kukana kwamankhwala kwa khansa ya prostate chifukwa cha kusintha kwina kwa AR.
Chimeric degraders ndi mamolekyu ang'onoang'ono omwe amagwira ntchito kawiri omwe amalimbikitsa kuwonongeka kwa mapuloteni omwe amawunikira omwe ali ndi mphamvu zambiri komanso kusankha kwakukulu. Ukadaulowu uli ndi kuthekera kolunjika kwa omwe sangamwe mankhwala osokoneza bongo komanso kuthana ndi vuto lakusamva mankhwala lamankhwala ang'onoang'ono amtundu wa molekyulu.
"Ichi ndi chofunikira kwambiri pakupita patsogolo kwa zoyesayesa zathu kuyambira pakupeza mankhwala osokoneza bongo mpaka kafukufuku wachipatala," adatero Yuanwei Chen, Ph.D., Purezidenti ndi CEO wa Hinova. "Ndife okondwa nazo ndipo tadzipereka kubweretsa njira zatsopano zothandizira odwala padziko lonse lapansi!"
Kupyolera mu njira yopezera mankhwala owononga mapuloteni, Hinova amatha kuyang'ana ntchito yowonongeka kwa mapuloteni mofulumira ndikukonzekera bwino komanso kukhathamiritsa kwa zowononga chimeric. Kuphatikiza apo, Hinova ali ndi chidziwitso chambiri pakuwongolera mankhwala opangira mankhwala a Chimeric degrader compounds.
ZOMWE MUNGACHITE PA NKHANIYI:
- Through the targeted protein degradation drug discovery platform, Hinova can screen protein degradation activity rapidly and accomplish efficient design and optimization of chimeric degraders.
- “This is a significant milestone in the progress of our efforts from drug discovery to the clinical study,”.
- This technology has the potential to target non-druggable targets and to overcome the drug resistance issue of traditional small molecule drugs.
